Literature DB >> 21502434

β-Catenin is a useful adjunct immunohistochemical marker for the diagnosis of pulmonary lymphangioleiomyomatosis.

Richard J Flavin1, Jennifer Cook, Michelangelo Fiorentino, Dyane Bailey, Myles Brown, Massimo F Loda.   

Abstract

Lymphangioleiomyomatosis (LAM) is a rare multisystem disease leading to cystic destruction of the lung parenchyma and is associated with abnormal smooth muscle proliferation affecting airways, lymphatics, and blood vessels. LAM occurs sporadically or in association with the tuberous sclerosis complex (TSC). Recent evidence demonstrates the role of aberrant β-catenin signaling in TSC. To further understand the pathogenesis of LAM and to examine the diagnostic usefulness of β-catenin, we examined protein expression in 28 pulmonary LAM cases and 10 cases of renal angiomyolipoma resected from patients with sporadic LAM. Immunohistochemical analysis was performed for established markers of LAM cells (HMB45, estrogen receptor [ER]-α, and progesterone receptor [PR]) and β-catenin. All LAM cases were positive for β-catenin and demonstrated high specificity with overall immunoreactivity superior to HMB45, ER-α, and PR. Similar expression was demonstrated in renal angiomyolipoma. Our results indicate that β-catenin is a useful marker of LAM and may be clinically useful in the diagnostic setting.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21502434     DOI: 10.1309/AJCPPC9EX1ZHMRMA

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  12 in total

Review 1.  The Lymphangioleiomyomatosis Lung Cell and Its Human Cell Models.

Authors:  Wendy K Steagall; Gustavo Pacheco-Rodriguez; Thomas N Darling; Olga Torre; Sergio Harari; Joel Moss
Journal:  Am J Respir Cell Mol Biol       Date:  2018-06       Impact factor: 6.914

Review 2.  Pulmonary Lymphangioleiomyomatosis: A Case Report and Literature Review.

Authors:  Sakda Sathirareuangchai; David Shimizu; Koah Robin Vierkoetter
Journal:  Hawaii J Health Soc Welf       Date:  2020-07-01

3.  Incidental Nodal Lymphangioleiomyomatosis Is Not a Harbinger of Pulmonary Lymphangioleiomyomatosis: A Study of 19 Cases With Evaluation of Diagnostic Immunohistochemistry.

Authors:  J Kenneth Schoolmeester; Kay J Park
Journal:  Am J Surg Pathol       Date:  2015-10       Impact factor: 6.394

4.  TSC2 regulates microRNA biogenesis via mTORC1 and GSK3β.

Authors:  Barbara Ogórek; Hilaire C Lam; Damir Khabibullin; Heng-Jia Liu; Julie Nijmeh; Robinson Triboulet; David J Kwiatkowski; Richard I Gregory; Elizabeth P Henske
Journal:  Hum Mol Genet       Date:  2018-05-01       Impact factor: 6.150

5.  Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation.

Authors:  Juxiang Cao; Magdalena E Tyburczy; Joel Moss; Thomas N Darling; Hans R Widlund; David J Kwiatkowski
Journal:  J Clin Invest       Date:  2016-12-05       Impact factor: 14.808

6.  In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor.

Authors:  Ling Gao; Michael M Yue; Jennifer Davis; Elisabeth Hyjek; Lucia Schuger
Journal:  Virchows Arch       Date:  2014-02-26       Impact factor: 4.064

Review 7.  Lymphangioleiomyomatosis - a wolf in sheep's clothing.

Authors:  Elizabeth P Henske; Francis X McCormack
Journal:  J Clin Invest       Date:  2012-11-01       Impact factor: 14.808

8.  EPIDEMIOLOGY, PATHOGENESIS and DIAGNOSIS of LYMPHANGIOLEIOMYOMATOSIS.

Authors:  Angelo M Taveira-DaSilva; Joel Moss
Journal:  Expert Opin Orphan Drugs       Date:  2016-03-07       Impact factor: 0.694

9.  Lymphangioleiomyomatosis: a case report and review of diagnosis and treatment.

Authors:  Yi Liu; Zhibin Guo; Chenlong Zhao; Xin Li; Hongyu Liu; Jun Chen
Journal:  Onco Targets Ther       Date:  2018-08-31       Impact factor: 4.147

10.  Therapeutic Strategies for Treatment of Pulmonary Lymphangioleiomyomatosis (LAM).

Authors:  Vera P Krymskaya
Journal:  Expert Opin Orphan Drugs       Date:  2014-08-27       Impact factor: 0.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.